If you are a client of Arnold & Itkin waiting on an Arnold & Itkin Risperdal settlement payout, the money has been moving in phases. Johnson & Johnson reached a settlement in principle in September 2021 covering substantially all outstanding U.S. gynecomastia cases, initial net disbursements to claimants went out in 2024, and a pro rata distribution of remaining holdback funds was approved as recently as December 2025.1SEC.gov. Johnson & Johnson Annual Report Filing2GovInfo. Moore v. Itkins, Case No. 4:25-CV-01180
Payout Timeline
The overall program resolved approximately 9,000 cases for roughly $800 million, with plaintiffs’ attorneys reporting an average individual settlement of about $95,000.3Wisner Baum. Risperdal Lawsuit A separate accounting of the Philadelphia-based litigation, where most cases were concentrated, valued the settlement at up to $1.1 billion.4The Legal Intelligencer. Up to $1.1 Billion: Inside the Settlement Resolving Most of Philadelphia’s Risperdal Cases
By April 2024, more than 5,600 of roughly 6,000 potential claimants had accepted their offers, a participation rate of 99.9%.5The Legal Intelligencer. How Can It Be Enough? Thousands Have Agreed to the Risperdal Settlement. A Few Holdouts Remain By late 2024, Johnson & Johnson reported that only seven plaintiffs with direct claims remained in pending Risperdal lawsuits.1SEC.gov. Johnson & Johnson Annual Report Filing For most claimants, the initial net check followed acceptance of the offer; holdback distributions came later.
How Much Claimants Received
The $95,000 average is a gross figure and hides a wide range. Individual amounts depended on the severity of the gynecomastia, economic losses, and the strength of the underlying case, and general damages for pain, suffering, and emotional distress differ significantly from case to case.3Wisner Baum. Risperdal Lawsuit
A federal court filing from Missouri shows the mechanics for one Arnold & Itkin client. The gross settlement was $98,409.94. Deductions took out $54,125.46 in attorneys’ fees, $19,150.23 in litigation expenses, and a $2,500 medical lien. The client received an initial net disbursement of $32,475.23 on October 9, 2024.2GovInfo. Moore v. Itkins, Case No. 4:25-CV-01180
The Pro Rata Holdback
The settlement agreement held back a portion of each claimant’s share during the initial payout phase and released it later. For the same Missouri client, the holdback phase produced two more payments: $15,163.89 from the global settlement holdback, approved for disbursement on December 19, 2025, and a separate check of $805.64 from a general expenses holdback fund. Notifications about these holdback funds went out in December 2025.2GovInfo. Moore v. Itkins, Case No. 4:25-CV-01180 Combined with the earlier disbursement, that client’s total net recovery came to $48,444.76 from a gross settlement just under $100,000.
If you were part of the Arnold & Itkin group, expect the same two-stage pattern: an initial net check after the settlement offer was accepted, then one or more holdback checks once the pro rata distribution was calculated and approved. The December 2025 notifications reflect that second stage.
If You Are Unhappy With the Fees or Amount
Two disputes over Arnold & Itkin’s handling of Risperdal settlements have gone through the courts, and both ended in the firm’s favor. In the Missouri case, Duan L. Moore sued Arnold & Itkin and co-counsel Kline & Specter, Sheller PC, and The Crouch Firm, alleging they had settled his case without permission and challenging the contingency fees taken from his proceeds. A federal court dismissed the lawsuit as “legally frivolous” on February 3, 2026, finding that Moore had signed valid engagement and settlement agreements and that his complaint amounted to dissatisfaction with the amount received rather than a viable legal claim.2GovInfo. Moore v. Itkins, Case No. 4:25-CV-01180 Moore filed a second, similar lawsuit in January 2026.
A separate dispute, Dupree v. Jason A. Itkin and Arnold & Itkin, LLP, moved through the Texas courts. The First Court of Appeals in Houston dismissed the case for lack of jurisdiction, and the Supreme Court of Texas denied review on August 1, 2025.6SCOTXblog. Dupree v. Itkin, No. 25-0451
What This Settlement Covers
The Arnold & Itkin Risperdal payouts resolve gynecomastia claims: abnormal breast growth in boys and young men prescribed Risperdal. A newer wave of lawsuits alleging that Risperdal causes breast cancer began in 2025 and is being litigated in California state court, but those cases involve different plaintiffs, different attorneys, and different legal theories than the gynecomastia settlement.3Wisner Baum. Risperdal Lawsuit A breast cancer claim is not part of the payout program covered here.